### Latest Developments in RSV Vaccines for Older Adults The FDA has approved the first vaccine for preventing respiratory syncytial virus (RSV) in older adults. This vaccine, called Arexvy, is produced by the British pharmaceutical company GSK and will be available by this fall. Arexvy is approved for people aged 60 and older. Clinical trials have shown that it can reduce the risk of severe complications from RSV, such as pneumonia and bronchitis, by up to 94%. However, the FDA has required GSK to conduct further research on Arexvy due to some serious health complications observed in the trials. One participant developed Guillain-Barré syndrome, a rare immune disorder, nine days after receiving the vaccine, and two others experienced a rare type of inflammation affecting the brain and spinal cord. RSV is a significant health concern, especially for older adults with underlying conditions like heart or lung disease or weakened immune systems. Each year, between 60,000 and 120,000 people are hospitalized due to RSV, and the virus contributes to up to 10,000 deaths annually among those aged 65 and older. Other pharmaceutical companies, such as Pfizer and Moderna, are also close to obtaining FDA approval for their own RSV vaccines. The demand for these vaccines is expected to be strong, with drugmakers potentially earning $10 billion by 2030 from RSV vaccines alone. GSK is projected to achieve $2.5 billion in peak sales for Arexvy. ### Conclusion The approval of Arexvy marks a significant milestone in the fight against RSV in older adults. With more vaccines on the horizon, there is hope for better prevention and management of this serious respiratory illness.